Table 2.

Association of Composite Physical Activity Score With Clinically Significant Increases in NT-proBNP^* Among All Patients With Baseline and Follow-up NT-proBNP

	Unadjusted (n = 2,933)	Demographic Variable† Adjusted (n = 2,933)	Comorbidity‡ Adjusted (n = 2,873)
Composite Activity Score
2 (n = 310, 10.6%)	Reference	Reference	Reference
3 (n = 461, 15.7%)	0.74 (0.54–1.02)	0.79 (0.58–1.09)	0.75 (0.53–1.04)
4 (n = 600, 20.5%)	0.52 (0.38–0.71)	0.56 (0.41–0.76)	0.56 (0.40–0.78)
5 (n = 688, 23.5%)	0.52 (0.38–0.70)	0.52 (0.38–0.70)	0.53 (0.39–0.74)
6 (n = 582, 19.8%)	0.58 (0.42–0.78)	0.60 (0.44–0.82)	0.60 (0.43–0.84)
7 (n = 292, 10.0%)	0.48 (0.33–0.71)	0.46 (0.31–0.69)	0.50 (0.33–0.76)
Test for trend	p < 0.001	p < 0.001	p = 0.001

Values are odds ratio (95% confidence interval).

^*Increase from baseline >25% and a follow-up NT-proBNP of >190 pg/ml. All models additionally adjusted for baseline NT-proBNP.

^†Demographic variables: age, sex, race, and education.

^‡Comorbidities: body mass index, diabetes, hypertension, coronary heart disease, claudication, emphysema, stroke, major electrocardiographic abnormality, and self-reported health.

NT-proBNP = N-terminal pro–B-type natriuretic peptide.